What is CompDrug?
CompDrug operates within the critical healthcare sector, specializing in providing medication-assisted treatment (MAT) for individuals struggling with opioid dependence. Their service portfolio includes essential treatments such as methadone, buprenorphine, and naltrexone, complemented by a range of outpatient programs and counseling options designed to foster sustained recovery. Beyond direct patient care, CompDrug actively engages in community health initiatives and preventative drug education for youth through its Youth to Youth program, positioning itself as a vital resource for both individuals seeking treatment and the broader community.
How much funding has CompDrug raised?
CompDrug has raised a total of $2.4M across 2 funding rounds:
Debt
$1M
Debt
$1.4M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.4M led by PPP
Key Investors in CompDrug
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for CompDrug?
The substantial enterprise-level funding and recent strategic investment signal a period of accelerated growth and expanded reach for CompDrug. This capital infusion is expected to bolster their treatment capacity, enhance their community outreach efforts, and potentially drive innovation in addiction treatment methodologies. The company's focus on a multi-faceted approach, combining clinical services with preventative education, positions it favorably to capitalize on increasing demand for effective substance use disorder solutions and to further solidify its role in public health.
See full CompDrug company page
